New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
19:49 EDTACRXAcelRX met primary endpoint in Phase 3 trial
AcelRx Pharmaceuticals announced it had met the primary endpoint in the Phase 3 non-inferiority study of the sublingual Sufentanil NanoTab PCA System vs. IV PCA with morphine. The top-line data is expected to be released prior to market opening on November 15. AcelRx management will host an conference call at 8:00 a.m. EST to discuss the Phase 3 top-line results.
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
10:00 EDTACRXOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: ASUR Airports (ASR) upgraded to Sector Perform from Underperform at Scotia Capital... AcelRx (ACRX) upgraded to Buy from Neutral at Mizuho... AllianceBernstein (AB) upgraded to Buy from Neutral at BofA/Merrill... American Express (AXP) upgraded to Buy from Hold at Deutsche Bank... Argus upgraded Sonoco (SON) on multiple positive catalysts... Columbia Property (CXP) upgraded to Neutral from Sell at Goldman... Deutsche sees American Express (AXP) as undervalued, upgrades to Buy... Eldorado Gold (EGO) upgraded to Neutral from Sell at Goldman... Genesee & Wyoming (GWR) upgraded to Buy from Neutral at BofA/Merrill... Gruma (GMK) upgraded to Overweight from Equal Weight at Barclays... Isle of Capri (ISLE) upgraded to Outperform from Neutral at Macquarie... JAKKS Pacific (JAKK) upgraded at B. Riley... QTS Realty Trust (QTS) upgraded to Buy from Hold at Deutsche Bank... Sonoco (SON) upgraded to Buy from Hold at Argus... T-Mobile (TMUS) upgraded to Buy from Neutral at Citigroup... Vulcan Materials (VMC) upgraded at RBC Capital.
06:22 EDTACRXAcelRx upgraded to Buy from Neutral at Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use